OVERVIEW

Utilizing Psychedelics to Provide Mental Health Support to Underserved and Vulnerable Populations is organized by UK HealthCare CECentral.

Start Date: Jun 1, 2024
End Date: Jun 1, 2027

Description:
According to the CDC 36,136 people received an HIV diagnosis in the United States and dependent areas in 2021. The annual number of new diagnoses decreased 7% from 2017 to 2021. It is critical for professionals to have current knowledge to provide effective treatment and education for patients. The CDC also states that Kentucky is at high risk for an HIV outbreak if introduced into the drug using population. HIV therapy was previously limited due to lack of treatment options, but more therapy options increase choice for patient treatment and challenges for providers. Screening for drug misuse is critical to the prevention of or early intervention in addiction.
Studies show that psilocybin is a safe and effective tool that can provide valuable benefit to a person's mental health and wellbeing. There is growing evidence showing that psilocybin can help provide relief from addiction, anxiety, depression, and other psychological issues like processing traumatic events.

Objectives:
Upon completion of this activity, participants will be able to:
• List the three components of psychedelic therapy in the Oregon Psilocybin Services model.
• List at least three reasons a patient would not be a good fit for psilocybin services.
• Assist patients in accessing psilocybin services.